Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc ACOGF


Primary Symbol: C.ACOG

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Alpha Cognition Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(144)
•••
Post by culturedpiggy01on Jan 17, 2022 4:02pm
76 Views
Post# 34325890

Interview with Michael McFadden, CEO of $ACOG

Interview with Michael McFadden, CEO of $ACOG
came across this great follow-up interview with Michael McFadden, CEO of $ACOG  where he recaps 2021 for $ACOG.v and discusses what’s in store for 2022 https://www.youtube.com/watch?v=VHCjmN1dR9g&t=1s brief and essential watch, specially if you’ve been following $ACOG.v for the past few months like I have
 
td, $ACOG.v trading at $1.06 with market cap at $65.19 M
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities